KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBITDA (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed EBITDA for 11 consecutive years, with -$130.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 184.08% to -$130.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$578.6 million through Dec 2025, down 57.95% year-over-year, with the annual reading at -$578.6 million for FY2025, 57.95% down from the prior year.
  • EBITDA hit -$130.8 million in Q4 2025 for CRISPR Therapeutics AG, down from -$105.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $759.1 million in Q2 2021 to a low of -$208.6 million in Q2 2025.
  • Historically, EBITDA has averaged -$68.5 million across 5 years, with a median of -$116.8 million in 2021.
  • Biggest five-year swings in EBITDA: surged 1052.88% in 2021 and later crashed 184.08% in 2025.
  • Year by year, EBITDA stood at -$145.5 million in 2021, then rose by 28.57% to -$104.0 million in 2022, then skyrocketed by 194.32% to $98.1 million in 2023, then crashed by 146.95% to -$46.0 million in 2024, then plummeted by 184.08% to -$130.8 million in 2025.
  • Business Quant data shows EBITDA for CRSP at -$130.8 million in Q4 2025, -$105.5 million in Q3 2025, and -$208.6 million in Q2 2025.